Table 1.
Clinicopathological features and immunohistochemical scores of well‐differentiated thyroid tumors of uncertain malignant potential (or well‐differentiated thyroid tumors of uncertain behavior)
| Case | Age (years) | Gender | Tumor size (cm) | Nuclei size (T/N) | Nuclear clearing | Nuclear grooves (%) | Follow‐up (months) | HBME‐1 | CK19 | GAL‐3 | BRAF mutation | RET/PTC1 rearrangement |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 39 | F | 4.6 | 3 | + | 3.0 | −† | +++ | − | − | − | − |
| 2 | 58 | M | 3.0 | 3 | + | 3.0 | −† | ++ | − | ++ | − | − |
| 3 | 47 | F | 3.0 | 2 | + | 1.0 | −† | − | − | − | − | − |
| 4 | 43 | F | 1.3 | 3 | + | 1.0 | 206 | ++ | ++ | ++ | − | − |
| 5 | 63 | F | 1.7 | 2 | + | 3.0 | 185 | − | − | − | − | − |
| 6 | 29 | M | 2.0 | 3 | + | 1.0 | 130 | − | + | − | − | − |
| 7 | 41 | F | 2.8 | 3 | + | 1.0 | −† | − | − | − | − | − |
| 8 | 36 | F | 1.1 | 3 | + | 3.0 | −† | − | − | − | − | − |
| 9 | 44 | F | 2.0 | 3 | + | 3.0 | 109 | +++ | − | − | − | − |
| 10 | 33 | F | 1.8 | 3 | + | 3.0 | −† | ++ | − | − | − | − |
| 11 | 50 | F | 1.0 | 3 | + | 3.0 | 89 | − | − | − | − | − |
| 12 | 44 | F | 1.5 | 3 | + | 3.0 | 87 | +++ | − | + | − | − |
| 13 | 35 | F | 0.9 | 3 | + | 3.0 | 74 | ++ | +++ | +++ | − | − |
| 14 | 46 | F | 1.6 | 2 | + | 1.0 | −† | +++ | + | ++ | − | − |
| 15 | 73 | F | 2.7 | 2 | + | 3.0 | 71 | − | − | − | − | − |
| 16 | 17 | F | 3.2 | 2 | + | 1.0 | 68 | − | − | − | − | − |
| 17 | 30 | F | 1.0 | 2 | + | 3.0 | 66 | − | − | − | − | − |
| 18 | 52 | F | 1.3 | 3 | + | 1.0 | 65 | ++ | − | − | − | − |
| 19 | 50 | F | 2.2 | 2 | + | 1.0 | 61 | − | +++ | − | − | − |
| 20 | 44 | M | 2.5 | 2 | + | 3.0 | 61 | +++ | +++ | +++ | − | − |
| 21 | 38 | F | 2.8 | 3 | + | 3.0 | 56 | − | − | − | − | − |
| 22 | 74 | F | 2.5 | 3 | + | 1.0 | 56 | − | +++ | − | − | − |
| 23 | 73 | F | 2.8 | 3 | + | 3.0 | 56 | +++ | − | ++ | − | + |
| 24 | 41 | F | 1.1 | 3 | + | 3.0 | 56 | − | − | − | − | − |
| 25 | 68 | M | 2.8 | 2 | + | 3.0 | −† | − | − | − | − | − |
| 26 | 80 | F | 1.5 | 2 | + | 1.0 | 43 | − | − | − | − | − |
| 27 | 64 | F | 2.6 | 2 | + | 1.0 | 42 | − | − | ++ | − | − |
| 28 | 35 | F | 1.5 | 3 | + | 3.0 | 35 | ++ | + | ++ | − | − |
| 29 | 53 | M | 1.0 | 3 | + | 3.0 | −† | − | ++ | ++ | − | + |
| 30 | 80 | F | 1.3 | 2 | + | 1.0 | −† | − | +++ | +++ | − | − |
†Follow‐up was not available. −, negative; +, positive; CK19, cytokeratin 19; F, female; GAL‐3, galectin‐3; M, male, T/N, nuclei size of the tumor cells versus that of normal thyroid follicular cells.